Ligand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational Transformation [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Net Income : Q4 net income from continuing operations was $18.2 million, a significant improvement from a net loss in the same period last year. Earnings Per Share (EPS) : Adjusted EPS for Q4 stood at $1.38, slightly up from $1.36 in Q4 2022. Cash Position : As of December 31, 2023, cash, cash equivalents, and short-term investments totaled $170.3 million. 2024 Financial Guidance : Ligand reaffirms its 2024 financial guidance with total revenue forecast of $130 million to $142 million. Warning! GuruFocus has detected 6 Warning Signs with LGND. Ligand Pharmaceuticals Inc ( NASDAQ:LGND ) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter and full year of 2023. The company, known for its partnerships and licensing agreements in the biopharmaceutical industry, has reported a year of transformation, focusing on becoming a lean-infrastructure, high-margin business. Ligand's revenue streams include royalties, license and milestone
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand and Agenus Enter Into $100 Million Royalty Financing AgreementBusiness Wire
- Don't Overlook These Top Medical Stocks as Q1 Earnings Approach [Yahoo! Finance]Yahoo! Finance
- Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio [Seeking Alpha]Seeking Alpha
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024Business Wire
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.MarketBeat
LGND
Earnings
- 2/27/24 - Beat
LGND
Sec Filings
- 5/7/24 - Form 8-K
- 5/2/24 - Form 4
- 4/26/24 - Form 4
- LGND's page on the SEC website